Targeting PI3K/Akt/mTOR Signaling in Cancer

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

(2015) Alberto M. Martelli et al.   Oncotarget

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

(2013) Eeva M. Sommer et al.   BIOCHEMICAL JOURNAL

Everolimus in Advanced Pancreatic Neuroendocrine Tumors: The Clinical Experience

(2013) J. C. Yao et al.   CANCER RESEARCH

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

(2013) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

Systemic Therapeutic Options for Carcinoid

(2013) Marianne Pavel et al.   SEMINARS IN ONCOLOGY

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy

(2013) Jing Tan et al.   Chinese Journal of Cancer

Targeting PI3K in Cancer: Any Good News?

(2013) Miriam Martini et al.   Frontiers in Oncology

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

(2012) M. M. Mita et al.   ANNALS OF ONCOLOGY

Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma

(2012) Laia Rosich et al.   Autophagy

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis

(2012) S Bracarda et al.   BRITISH JOURNAL OF CANCER

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma

(2012) L. Rosich et al.   CLINICAL CANCER RESEARCH

Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going?

(2012) Palma Fedele et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial

(2012) Camillo Porta et al.   EUROPEAN UROLOGY

Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy

(2012) J. S. Logue et al.   GENES & DEVELOPMENT

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications

(2012) Jean-Yves Scoazec   NEUROENDOCRINOLOGY

Cross-Talk between NFkB and the PI3-Kinase/AKT Pathway Can Be Targeted in Primary Effusion Lymphoma (PEL) Cell Lines for Efficient Apoptosis

(2012) Azhar R. Hussain et al.   PLoS One

Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway

(2011) Domenico Ribatti   CANCER TREATMENT REVIEWS

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma

(2011) Camillo Porta et al.   EUROPEAN JOURNAL OF CANCER

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

(2011) E. Calvo et al.   EUROPEAN JOURNAL OF CANCER

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

(2011) James C. Yao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

(2011) N. Ilic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autophagy is a therapeutic target in anticancer drug resistance

(2010) Suning Chen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer

(2010) Jing Tan et al.   CANCER CELL

Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy

(2010) Amir Abdollahi et al.   DRUG RESISTANCE UPDATES

Akt inhibitors in clinical development for the treatment of cancer

(2010) Sumanta Kumar Pal et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway

(2010) Karine Villaume et al.   NEUROENDOCRINOLOGY

Akt-dependent and -independent mechanisms of mTOR regulation in cancer

(2009) Regan M. Memmott et al.   CELLULAR SIGNALLING

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the Therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors

(2009) Camillo Porta et al.   JOURNAL OF UROLOGY

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

(2008) Arkaitz Carracedo et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET